GlaxoSmithKline plc (ADR) Could Decline a Lot According to The Today’s Call Option Activity

 GlaxoSmithKline plc (ADR) Could Decline a Lot According to The Today's Call Option Activity

In today’s session GlaxoSmithKline plc (ADR) (GSK) recorded an unusually high (210) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious GSK decrease. With 210 contracts traded and 10214 open interest for the Jan, 17 contract, it seems this is a quite bearish bet. The option with symbol: GSK170120P00038000 closed last at: $0.85 or 26.1% down. About 554,373 shares traded hands. GlaxoSmithKline plc (ADR) (NYSE:GSK) has declined 10.35% since April 26, 2016 and is downtrending. It has underperformed by 15.61% the S&P500.

Analysts await GlaxoSmithKline plc (ADR) (NYSE:GSK) to report earnings on February, 1. They expect $0.63 EPS, up 14.55% or $0.08 from last year’s $0.55 per share. GSK’s profit will be $1.51B for 15.17 P/E if the $0.63 EPS becomes a reality. After $0.83 actual EPS reported by GlaxoSmithKline plc (ADR) for the previous quarter, Wall Street now forecasts -24.10% negative EPS growth.

GlaxoSmithKline plc (ADR) (NYSE:GSK) Ratings Coverage

Out of 11 analysts covering GlaxoSmithKline (NYSE:GSK), 6 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 55% are positive. $50 is the highest target while $40 is the lowest. The $47.50 average target is 24.28% above today’s ($38.22) stock price. GlaxoSmithKline has been the topic of 16 analyst reports since September 8, 2015 according to StockzIntelligence Inc. The stock has “Underperform” rating given by BNP Paribas on Wednesday, September 14. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) earned “Buy” rating by Jefferies on Thursday, July 14. The stock has “Neutral” rating given by BNP Paribas on Tuesday, September 15. The firm has “Buy” rating by Investec given on Thursday, October 20. On Wednesday, December 9 the stock rating was upgraded by Bank of America to “Buy”. The rating was maintained by Argus Research on Friday, August 12 with “Buy”. Argus Research maintained the stock with “Buy” rating in Monday, December 7 report. Credit Suisse upgraded the shares of GSK in a report on Tuesday, October 20 to “Neutral” rating. As per Friday, September 23, the company rating was initiated by Piperjaffray. The company was upgraded on Monday, October 12 by JP Morgan.

According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.”

GlaxoSmithKline plc is a healthcare company. The company has a market cap of $91.38 billion. The Firm is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. It has a 256.75 P/E ratio. The Company’s divisions include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

GSK Company Profile

GlaxoSmithKline plc (GSK), incorporated on December 6, 1999, is a healthcare company. The Firm is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company’s divisions include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

More news for GlaxoSmithKline plc (ADR) (NYSE:GSK) were recently published by: Businessfinancenews.com, which released: “GlaxoSmithKline plc (ADR) Earning Release; Here’s What to Expect” on July 26, 2016. Businessfinancenews.com‘s article titled: “Can GlaxoSmithKline plc (ADR) Subsist Advair’s Patent Expiry” and published on June 25, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment